PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Articles

Search & filter insights:

Search & filter insights:

Use of AI in the patent industry: The spectre of hallucination

  • 10th October 2025
What are the risks of AI hallucinations for the patent industry?

Use of AI in the patent industry: Solving the confidentiality problem

  • 10th October 2025
How can patent attorneys ensure client confidentiality when using AI software for patents.

Evolve AI: Building AI tools for IP that are expert-led and pharma-specific

  • 2nd October 2025
We believe that the value of AI for our profession lies in developing highly specialised tools that build upon and incorporate domain-specific attorney expertise.

Is it time for patent offices to enter the bioinformatic age?

  • 13th June 2025
In a world in which incalculable amounts of sophisticated sequence data is freely available, are the clunky processes necessary to input patent sequence data really fit-for-purpose?

An LLM is not (yet) a person skilled in the art (T 1193/23)

  • 20th May 2025
The EPO clarifies that an LLM interpretation of a technical term in a patent is not yet evidence of how a skilled person would interpret the term.

OpenAI’s large language model (LLM) patents

  • 29th April 2025
For tech innovators seeking to understand evolving intellectual property strategies, OpenAI’s recent pivot offers essential guidance: far from relying solely on trade secrets, the AI leader is now aggressively pursuing and accelerating patent grants, signaling a significant shift.

“Using AI tools to help assess inventive step”: A response to the CIPA journal article

  • 16th July 2024
This post is based on a previous article on IPKat. The cover article of the May 2024 edition of the CIPA Journal proposed a new test for inventive step using AI. The article was inspired by the EPO’s AI assisted search tool, AI-PreSearch. The CIPA journal article proposes to use an AI derived measurement of semantic similarity between the…

When is the inventor of an AI model also an inventor of the model’s output? A closer look at the USPTO Guidance for AI-Assisted Inventions

  • 16th July 2024
According to the USPTO guidance for AI-assisted inventions, AI has the potential to solve some of society’s most difficult challenges. However, in the patent realm, the USPTO also believes that “inventorship analysis should focus on human contributions, as patents function to incentivize and reward human ingenuity”. How then are AI-generated inventions to be protected?…

Use of large language models in the patent industry: A risk to patent quality?

  • 16th November 2023
This post is based on a previous article on IPKat. Large language models (LLMs) such as ChatGPT have been hailed as potentially revolutionary for the legal industry. Lord Justice Birss himself recently made headlines for praising the usefulness of ChatGPT for writing court judgments. LLMs are undeniably a major technological advance with the potential to make a significant…

Bad cases make bad law: Has DABUS “the AI inventor” actually invented anything?

  • 16th September 2023
In keeping with the so-called media “silly season” of late summer, we thought we would check-in on the AI inventor debate. We have been sceptical about Dr Thaler and his purported inventing machine, DABUS, for some time. A recent EPO Examining Division office action appears to share similar concerns. 

Artificial intelligence is not breaking patent law: EPO publishes DABUS decision (J 8/20)

  • 16th August 2022
This post is based on a previous article on IPKat. The EPO Board of Appeal has published its full decision on the question of whether a machine can be an inventor (J 8/20). The Board of Appeal had previously announced its decision to refuse two European patent applications naming an algorithm (“DABUS”) as the sole inventor…

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us